Advancing End-to-End Automated Manufacturing to Accelerate Autologous Cell Therapy Development Without Compromising Approval Timelines
- Implementing high-level automation strategies in parallel with ongoing clinical development to advance technology without impacting critical product approval timelines
- Transferring existing manual manufacturing platforms into fully automated end-to-end systems while managing comparability risks and maintaining process consistency
- Applying regulatory interaction lessons learned during automation implementation to navigate compliance requirements and avoid costly development timeline disruptions